Page last updated: 2024-10-30

metformin and Erdheim-Chester Disease

metformin has been researched along with Erdheim-Chester Disease in 1 studies

Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289)
metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.

Erdheim-Chester Disease: A rare form of non-Langerhans-cell histiocytosis (HISTIOCYTOSIS, NON-LANGERHANS-CELL) with onset in middle age. The systemic disease is characterized by infiltration of lipid-laden macrophages, multinucleated giant cells, an inflammatory infiltrate of lymphocytes and histiocytes in the bone marrow, and a generalized sclerosis of the long bones.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Balink, H1
Hemmelder, MH1
de Graaf, W1
Grond, J1

Other Studies

1 other study available for metformin and Erdheim-Chester Disease

ArticleYear
Scintigraphic diagnosis of Erdheim-Chester disease.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, Jun-01, Volume: 29, Issue:16

    Topics: Aged; Amlodipine; Antihypertensive Agents; Diabetes Mellitus, Type 2; Drug Combinations; Erdheim-Che

2011